Status:

COMPLETED

The Role of oAncreatic Enzyme ReplAcement Therapy (PERT) on Mucosal Visibility Before Upper GI Endoscopy

Lead Sponsor:

Carol Davila University of Medicine and Pharmacy

Conditions:

Upper Gastrointestinal Endoscopy

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The investigators aim to establish wether the administration of pancreatic enzyme replacement therapy (PERT) improves visibility of the mucosa during upper gastrointestinal endoscopy.

Detailed Description

Upper gastrointestinal endoscopy is done "a jeun", without any solid foods at least 8 hours before procedure and no water at least 2 hours before procedure. Often, the visibility of the mucosa is sub...

Eligibility Criteria

Inclusion

  • patient with upper gastrointestinal endoscopy indication, with topical pharyngeal anesthesia
  • age above 18 years old
  • informed consent

Exclusion

  • allergy to KREON and/or sodium bicarbonate
  • upper gastrointestinal bleeding clinically manifest (hematemesis, melena, hematochesia)
  • ingested foreign body
  • personal history of esophagectomy, partial or total gastectomy
  • absence of informed consent

Key Trial Info

Start Date :

August 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2024

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT06218537

Start Date

August 1 2024

End Date

August 31 2024

Last Update

November 12 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

"Agrippa Ionescu" Hospital

Bucharest, Romania